Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab plus statin therapy in symptomatic intracranial/extracranial atherosclerotic stenosis
ChiCTR2400088792Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of evolocumab in ischemic stroke, Cerebral atherosclerotic stenosis (ICAD), carotid atheroma (CAS) and 3 more (2 arms), sponsored by The Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: early recurrent stroke (ERS). Planned start Aug 2024; status: not yet recruiting.
02
Drugs
evolocumab
03
Conditions
ischemic strokeCerebral atherosclerotic stenosis (ICAD)carotid atheroma (CAS)Vertebral artery stenosis (VBI)basilar artery stenosis (BAS)
Beyond the preview
Go deeper on ChiCTR2400088792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088792.